Trial · NCT06309472
Trial of Mirtazapine for Depression in IBD
NCT06309472, Phase 2, Completed, King's College London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Mirtazapine for Depression in IBD. Trials, record NCT06309472. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06309472
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Mirtazapine for Depression in IBD
- NCT number
- NCT06309472
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 76 participants, actual
- Lead sponsor
- King's College London
- Conditions
- Major Depressive Disorder, Inflammatory Bowel Diseases
- Interventions
- Mirtazapine, Placebo
- First posted
- 2024-03-13
- Last updated
- 2026-08-19
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment feasibility | Up to 2 years | Participants randomised overall, percentage of target |
| Primary | Trial adherence | 12 weeks | Percentage of participants completing 12 weeks of treatment |
| Primary | Treatment adherence | 12 weeks | Percentage of participants taking at least 75% of prescribed mediation |
| Primary | Study procedures acceptability and compliance | 12 weeks | Percentage of planned data and samples collected at primary endpoint (12 weeks) |
| Primary | Overall acceptability | 12 weeks | Percentage of participants describing the treatment as acceptable (≥6/10 on 0-10 scale) |
| Secondary | Quick Inventory for Depressive Symptomatology-16 Questionnaire | Baseline, 4, 8, 12 and 16 weeks | Range 0-27, higher scores indicate worse depressive symptoms |
| Secondary | Patient Health Questionnaire-9 questionnaire | Baseline, 4, 8, 12 and 16 weeks | Range 0-27, higher scores indicate worse depressive symptoms |
| Secondary | Generalised Anxiety Disorder-7 questionnaire | Baseline, 4, 8, 12 and 16 weeks | Range 0-21, higher scores indicate worse anxiety symptoms |
| Secondary | Inflammatory Bowel Disease Control questionnaire | Baseline, 4, 8, 12 and 16 weeks | Range 0-16, higher scores indicate better self-report IBD control |
| Secondary | Inflammatory Bowel Disease Fatigue Assessment Scale | Baseline, 4, 8, 12 and 16 weeks | Range 0-20, higher scores indicate worse fatigue severity |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06309472
GET https://conductscience.org/api/trials/v1/NCT06309472/registered?page=2